Continuum Advisory’s Xenon Pharmaceuticals XENE Stock Holding History

Continuum Advisory’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.9K	Buy	+48	New	+$2.67K	﹤0.01%	1637
2025 Q2	–	Sell	-27	Closed	-$906	–	1601
2025 Q1	$906	Hold	27	–	–	﹤0.01%	1520
2024 Q4	$1.06K	Hold	27	–	–	﹤0.01%	1603
2024 Q3	$1.13K	Buy	27 +12	+80%	+$484	﹤0.01%	1597
2024 Q2	$585	Hold	15	–	–	﹤0.01%	1572
2024 Q1	$637	Buy	+15	New	+$690	﹤0.01%	1562

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Continuum Advisory's XENE Position: Q2 2026 in Review

Continuum Advisory opened a new position in Xenon Pharmaceuticals (XENE) in Q2 2026: 48 shares worth $2.9K. The stake represents ﹤0.01% of the portfolio and ranks #1637 among its holdings. This is a return to the name: Continuum Advisory previously reported a position in XENE as recently as Q1 2025.

Continuum Advisory first reported a position in XENE in Q1 2024 and has held it in 6 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Continuum Advisory held 48 shares of Xenon Pharmaceuticals worth $2.9K as of Q2 2026.
Xenon Pharmaceuticals was a new Continuum Advisory position in Q2 2026.
Xenon Pharmaceuticals made up ﹤0.01% of Continuum Advisory's portfolio in Q2 2026, its #1637 holding.
Continuum Advisory first reported a position in Xenon Pharmaceuticals in Q1 2024 and has held it in 6 quarters since.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Continuum Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.